Medifast (NYSE:MED) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Medifast (NYSE:MED) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other analysts also recently weighed in on MED. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. Stephens decreased their price target on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, February 19th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $12.00.

Medifast Stock Performance

Medifast stock opened at $10.11 on Friday. The stock has a 50-day moving average of $10.89 and a two-hundred day moving average of $11.77. Medifast has a one year low of $9.22 and a one year high of $15.46. The stock has a market cap of $111.11 million, a PE ratio of -5.91 and a beta of 0.52.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The business had revenue of $75.10 million for the quarter, compared to analyst estimates of $71.40 million. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. As a group, sell-side analysts predict that Medifast will post 0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MED. Corient Private Wealth LLC purchased a new stake in Medifast in the fourth quarter valued at approximately $139,000. Empowered Funds LLC raised its position in Medifast by 11.1% during the 4th quarter. Empowered Funds LLC now owns 44,773 shares of the specialty retailer’s stock worth $478,000 after buying an additional 4,462 shares during the last quarter. Man Group plc lifted its stake in Medifast by 10.8% during the 4th quarter. Man Group plc now owns 236,500 shares of the specialty retailer’s stock valued at $2,526,000 after acquiring an additional 23,070 shares during the period. Trexquant Investment LP lifted its stake in Medifast by 88.0% during the 4th quarter. Trexquant Investment LP now owns 126,959 shares of the specialty retailer’s stock valued at $1,356,000 after acquiring an additional 59,439 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Medifast by 24.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,905 shares of the specialty retailer’s stock valued at $245,000 after acquiring an additional 4,500 shares during the last quarter. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.